InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-02-25

AUTHORS

Tadej Battelino, Zsolt Bosnyak, Thomas Danne, Bhaswati Mukherjee, Steve Edelman, Valerie Pilorget, Pratik Choudhary, Eric Renard, Richard Bergenstal

ABSTRACT

IntroductionSuboptimal glycaemic control among people with type 1 diabetes (T1D) is known to lead to long-term micro- and macrovascular complications and, unfortunately, it is still prevalent even in the most affluent societies. Although glycated haemoglobin monitoring is considered to be the gold standard for assessing glycaemic control, such monitoring is unable to reliably measure acute glycaemic excursions. Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions. The use of CGM has led to time-in-range, which is the time that a patient is within the glycaemic range of 70 to 180 mg/dL, to be adopted as a treatment target. To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100) in people with T1D are available, and there is no CGM literature on comparisons of the use of CGM results to assess primary, secondary and tertiary endpoints. The aim of the InRange study was to address this unmet need.MethodsInRange is a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4, comparative study. Adults with T1D will be randomised to receive once-daily Gla-300 or IDeg-100 by subcutaneous injection in the morning. Following an 8-week titration period, CGM data will be collected over 20 consecutive days.Planned outcomesThe primary objective is to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control [time-in-range ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)] and variability, as assessed using CGM, in adults with T1D. The results are expected to help confirm the utility of CGM in clinical practice in this population and provide insight into its application as an outcome measure in clinical practice.Trial registrationNCT04075513.7DcEiszFv55fk51_GYesn2Video Abstract More... »

PAGES

1017-1027

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-020-00781-6

DOI

http://dx.doi.org/10.1007/s13300-020-00781-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1125112320

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32100192


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "UMC\u2013University Children\u2019s Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia", 
          "id": "http://www.grid.ac/institutes/grid.8954.0", 
          "name": [
            "UMC\u2013University Children\u2019s Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Battelino", 
        "givenName": "Tadej", 
        "id": "sg:person.01222441663.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222441663.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi S.A., Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi S.A., Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bosnyak", 
        "givenName": "Zsolt", 
        "id": "sg:person.01341321261.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341321261.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Centre for Children and Adolescents, Children\u2019s and Youth Hospital \u201cAuf Der Bult\u201d, Hannover, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Diabetes Centre for Children and Adolescents, Children\u2019s and Youth Hospital \u201cAuf Der Bult\u201d, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Danne", 
        "givenName": "Thomas", 
        "id": "sg:person.012437421415.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012437421415.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi S.A., Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi S.A., Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukherjee", 
        "givenName": "Bhaswati", 
        "id": "sg:person.014750372124.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014750372124.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266100.3", 
          "name": [
            "University of California, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Edelman", 
        "givenName": "Steve", 
        "id": "sg:person.0645521561.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645521561.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi S.A., Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi S.A., Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pilorget", 
        "givenName": "Valerie", 
        "id": "sg:person.0625112120.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625112120.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Diabetes, School of Life Course Sciences, King\u2019s College London, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.13097.3c", 
          "name": [
            "King\u2019s College Hospital NHS Foundation Trust, London, UK", 
            "Department of Diabetes, School of Life Course Sciences, King\u2019s College London, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choudhary", 
        "givenName": "Pratik", 
        "id": "sg:person.0665052610.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665052610.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM Clinical Investigation Centre, Montpellier, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, University of Montpellier, Montpellier, France", 
            "Institute of Functional Genomics, University of Montpellier, Montpellier, France", 
            "INSERM Clinical Investigation Centre, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Renard", 
        "givenName": "Eric", 
        "id": "sg:person.01045537314.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045537314.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International Diabetes Center at Park Nicollet, Minneapolis, USA", 
          "id": "http://www.grid.ac/institutes/grid.417226.4", 
          "name": [
            "International Diabetes Center at Park Nicollet, Minneapolis, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bergenstal", 
        "givenName": "Richard", 
        "id": "sg:person.01007144437.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007144437.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40262-014-0165-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012376480", 
          "https://doi.org/10.1007/s40262-014-0165-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-019-05080-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1124336729", 
          "https://doi.org/10.1007/s00125-019-05080-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-02-25", 
    "datePublishedReg": "2020-02-25", 
    "description": "IntroductionSuboptimal glycaemic control among people with type 1 diabetes (T1D) is known to lead to long-term micro- and macrovascular complications and, unfortunately, it is still prevalent even in the most affluent societies. Although glycated haemoglobin monitoring is considered to be the gold standard for assessing glycaemic control, such monitoring is unable to reliably measure acute glycaemic excursions. Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions. The use of CGM has led to time-in-range, which is the time that a patient is within the glycaemic range of 70 to 180 mg/dL, to be adopted as a treatment target. To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100\u00a0U/mL (IDeg-100) in people with T1D are available, and there is no CGM literature on comparisons of the use of CGM results to assess primary, secondary and tertiary endpoints. The aim of the InRange study was to address this unmet need.MethodsInRange is a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4, comparative study. Adults with T1D will be randomised to receive once-daily Gla-300 or IDeg-100 by subcutaneous injection in the morning. Following an 8-week titration period, CGM data will be collected over 20 consecutive days.Planned outcomesThe primary objective is to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control [time-in-range\u2009\u2265\u200970 to\u2009\u2264\u2009180\u00a0mg/dL (\u2265\u20093.9 to\u2009\u2264\u200910\u00a0mmol/L)] and variability, as assessed using CGM, in adults with T1D. The results are expected to help confirm the utility of CGM in clinical practice in this population and provide insight into its application as an outcome measure in clinical practice.Trial registrationNCT04075513.7DcEiszFv55fk51_GYesn2Video Abstract", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-020-00781-6", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.4455643", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "continuous glucose monitoring", 
      "glycaemic control", 
      "IDeg-100", 
      "Gla-300", 
      "clinical practice", 
      "glargine 300 U/mL", 
      "use of CGM", 
      "glycated hemoglobin monitoring", 
      "daily Gla-300", 
      "incidence of hypoglycaemia", 
      "long-term micro", 
      "overall glycaemic control", 
      "type 1 diabetes", 
      "second-generation insulins", 
      "hypoglycaemic excursions", 
      "tertiary endpoints", 
      "macrovascular complications", 
      "titration period", 
      "glycaemic excursions", 
      "glucose control", 
      "subcutaneous injection", 
      "outcome measures", 
      "hemoglobin monitoring", 
      "treatment targets", 
      "unmet need", 
      "glycaemic range", 
      "type 1", 
      "consecutive days", 
      "CGM results", 
      "glucose monitoring", 
      "gold standard", 
      "limited data", 
      "CGM data", 
      "T1D", 
      "adults", 
      "phase 4", 
      "complete assessment", 
      "primary objective", 
      "multicentre", 
      "hypoglycaemia", 
      "T1D.", 
      "complications", 
      "patients", 
      "diabetes", 
      "mL", 
      "control", 
      "incidence", 
      "dl", 
      "insulin", 
      "trials", 
      "endpoint", 
      "affluent societies", 
      "injection", 
      "such monitoring", 
      "study", 
      "days", 
      "monitoring", 
      "hyper", 
      "people", 
      "morning", 
      "comparative study", 
      "aim", 
      "population", 
      "excursion", 
      "persons", 
      "use", 
      "practice", 
      "assessment", 
      "target", 
      "period", 
      "data", 
      "measures", 
      "time", 
      "date", 
      "comparison", 
      "utility", 
      "objective", 
      "results", 
      "need", 
      "literature", 
      "standards", 
      "variability", 
      "range", 
      "insights", 
      "society", 
      "terms", 
      "design", 
      "micro", 
      "applications"
    ], 
    "name": "InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring\u2014Study Design", 
    "pagination": "1017-1027", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1125112320"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-020-00781-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32100192"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-020-00781-6", 
      "https://app.dimensions.ai/details/publication/pub.1125112320"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_849.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-020-00781-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00781-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00781-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00781-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00781-6'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      21 PREDICATES      116 URIs      106 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-020-00781-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N69966819b37d40b79b6102a8ea1e7b9e
4 schema:citation sg:pub.10.1007/s00125-019-05080-9
5 sg:pub.10.1007/s40262-014-0165-y
6 schema:datePublished 2020-02-25
7 schema:datePublishedReg 2020-02-25
8 schema:description IntroductionSuboptimal glycaemic control among people with type 1 diabetes (T1D) is known to lead to long-term micro- and macrovascular complications and, unfortunately, it is still prevalent even in the most affluent societies. Although glycated haemoglobin monitoring is considered to be the gold standard for assessing glycaemic control, such monitoring is unable to reliably measure acute glycaemic excursions. Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions. The use of CGM has led to time-in-range, which is the time that a patient is within the glycaemic range of 70 to 180 mg/dL, to be adopted as a treatment target. To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100) in people with T1D are available, and there is no CGM literature on comparisons of the use of CGM results to assess primary, secondary and tertiary endpoints. The aim of the InRange study was to address this unmet need.MethodsInRange is a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4, comparative study. Adults with T1D will be randomised to receive once-daily Gla-300 or IDeg-100 by subcutaneous injection in the morning. Following an 8-week titration period, CGM data will be collected over 20 consecutive days.Planned outcomesThe primary objective is to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control [time-in-range ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)] and variability, as assessed using CGM, in adults with T1D. The results are expected to help confirm the utility of CGM in clinical practice in this population and provide insight into its application as an outcome measure in clinical practice.Trial registrationNCT04075513.7DcEiszFv55fk51_GYesn2Video Abstract
9 schema:genre article
10 schema:isAccessibleForFree true
11 schema:isPartOf N64e4b1a210b44db4837dc2ed56b021e8
12 N73ac8be3cbb14908b946815cfdd33110
13 sg:journal.1044057
14 schema:keywords CGM data
15 CGM results
16 Gla-300
17 IDeg-100
18 T1D
19 T1D.
20 adults
21 affluent societies
22 aim
23 applications
24 assessment
25 clinical practice
26 comparative study
27 comparison
28 complete assessment
29 complications
30 consecutive days
31 continuous glucose monitoring
32 control
33 daily Gla-300
34 data
35 date
36 days
37 design
38 diabetes
39 dl
40 endpoint
41 excursion
42 glargine 300 U/mL
43 glucose control
44 glucose monitoring
45 glycaemic control
46 glycaemic excursions
47 glycaemic range
48 glycated hemoglobin monitoring
49 gold standard
50 hemoglobin monitoring
51 hyper
52 hypoglycaemia
53 hypoglycaemic excursions
54 incidence
55 incidence of hypoglycaemia
56 injection
57 insights
58 insulin
59 limited data
60 literature
61 long-term micro
62 mL
63 macrovascular complications
64 measures
65 micro
66 monitoring
67 morning
68 multicentre
69 need
70 objective
71 outcome measures
72 overall glycaemic control
73 patients
74 people
75 period
76 persons
77 phase 4
78 population
79 practice
80 primary objective
81 range
82 results
83 second-generation insulins
84 society
85 standards
86 study
87 subcutaneous injection
88 such monitoring
89 target
90 terms
91 tertiary endpoints
92 time
93 titration period
94 treatment targets
95 trials
96 type 1
97 type 1 diabetes
98 unmet need
99 use
100 use of CGM
101 utility
102 variability
103 schema:name InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design
104 schema:pagination 1017-1027
105 schema:productId N8f214e87b2c64460a3b0edfd3944d93e
106 Ncfcf90b90d4e468a9fff2470364b608c
107 Nfc5e100670dc44a390f699149b6b4963
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125112320
109 https://doi.org/10.1007/s13300-020-00781-6
110 schema:sdDatePublished 2022-11-24T21:05
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher Nca3e5d0c6e2845408b1d671a848f6679
113 schema:url https://doi.org/10.1007/s13300-020-00781-6
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N06630bd7b5484d0989a4cac024cc54e1 rdf:first sg:person.0625112120.31
118 rdf:rest Nd0bbba08f32d42cdbf337c6ee17aee45
119 N2a016da01e484292909dce1c40ec3e2d rdf:first sg:person.01045537314.24
120 rdf:rest Nff65e54c078d4d3da67a87203a3f921c
121 N3807295a322a499b8a7bfbbfec1a8a13 rdf:first sg:person.014750372124.55
122 rdf:rest N5e040c1dc36345b9895b5d5de5274bcc
123 N5e040c1dc36345b9895b5d5de5274bcc rdf:first sg:person.0645521561.23
124 rdf:rest N06630bd7b5484d0989a4cac024cc54e1
125 N64e4b1a210b44db4837dc2ed56b021e8 schema:issueNumber 4
126 rdf:type schema:PublicationIssue
127 N69966819b37d40b79b6102a8ea1e7b9e rdf:first sg:person.01222441663.40
128 rdf:rest N80981bae50cd478d930a18daa1c1facb
129 N73ac8be3cbb14908b946815cfdd33110 schema:volumeNumber 11
130 rdf:type schema:PublicationVolume
131 N80981bae50cd478d930a18daa1c1facb rdf:first sg:person.01341321261.23
132 rdf:rest N8de374e6b87840ffa5eedf6d2dfd1595
133 N8de374e6b87840ffa5eedf6d2dfd1595 rdf:first sg:person.012437421415.53
134 rdf:rest N3807295a322a499b8a7bfbbfec1a8a13
135 N8f214e87b2c64460a3b0edfd3944d93e schema:name dimensions_id
136 schema:value pub.1125112320
137 rdf:type schema:PropertyValue
138 Nca3e5d0c6e2845408b1d671a848f6679 schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 Ncfcf90b90d4e468a9fff2470364b608c schema:name pubmed_id
141 schema:value 32100192
142 rdf:type schema:PropertyValue
143 Nd0bbba08f32d42cdbf337c6ee17aee45 rdf:first sg:person.0665052610.61
144 rdf:rest N2a016da01e484292909dce1c40ec3e2d
145 Nfc5e100670dc44a390f699149b6b4963 schema:name doi
146 schema:value 10.1007/s13300-020-00781-6
147 rdf:type schema:PropertyValue
148 Nff65e54c078d4d3da67a87203a3f921c rdf:first sg:person.01007144437.64
149 rdf:rest rdf:nil
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:grant.4455643 http://pending.schema.org/fundedItem sg:pub.10.1007/s13300-020-00781-6
157 rdf:type schema:MonetaryGrant
158 sg:journal.1044057 schema:issn 1869-6953
159 1869-6961
160 schema:name Diabetes Therapy
161 schema:publisher Springer Nature
162 rdf:type schema:Periodical
163 sg:person.01007144437.64 schema:affiliation grid-institutes:grid.417226.4
164 schema:familyName Bergenstal
165 schema:givenName Richard
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007144437.64
167 rdf:type schema:Person
168 sg:person.01045537314.24 schema:affiliation grid-institutes:None
169 schema:familyName Renard
170 schema:givenName Eric
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045537314.24
172 rdf:type schema:Person
173 sg:person.01222441663.40 schema:affiliation grid-institutes:grid.8954.0
174 schema:familyName Battelino
175 schema:givenName Tadej
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222441663.40
177 rdf:type schema:Person
178 sg:person.012437421415.53 schema:affiliation grid-institutes:None
179 schema:familyName Danne
180 schema:givenName Thomas
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012437421415.53
182 rdf:type schema:Person
183 sg:person.01341321261.23 schema:affiliation grid-institutes:grid.417924.d
184 schema:familyName Bosnyak
185 schema:givenName Zsolt
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341321261.23
187 rdf:type schema:Person
188 sg:person.014750372124.55 schema:affiliation grid-institutes:grid.417924.d
189 schema:familyName Mukherjee
190 schema:givenName Bhaswati
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014750372124.55
192 rdf:type schema:Person
193 sg:person.0625112120.31 schema:affiliation grid-institutes:grid.417924.d
194 schema:familyName Pilorget
195 schema:givenName Valerie
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625112120.31
197 rdf:type schema:Person
198 sg:person.0645521561.23 schema:affiliation grid-institutes:grid.266100.3
199 schema:familyName Edelman
200 schema:givenName Steve
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645521561.23
202 rdf:type schema:Person
203 sg:person.0665052610.61 schema:affiliation grid-institutes:grid.13097.3c
204 schema:familyName Choudhary
205 schema:givenName Pratik
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665052610.61
207 rdf:type schema:Person
208 sg:pub.10.1007/s00125-019-05080-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124336729
209 https://doi.org/10.1007/s00125-019-05080-9
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/s40262-014-0165-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1012376480
212 https://doi.org/10.1007/s40262-014-0165-y
213 rdf:type schema:CreativeWork
214 grid-institutes:None schema:alternateName Diabetes Centre for Children and Adolescents, Children’s and Youth Hospital “Auf Der Bult”, Hannover, Germany
215 INSERM Clinical Investigation Centre, Montpellier, France
216 schema:name Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, University of Montpellier, Montpellier, France
217 Diabetes Centre for Children and Adolescents, Children’s and Youth Hospital “Auf Der Bult”, Hannover, Germany
218 INSERM Clinical Investigation Centre, Montpellier, France
219 Institute of Functional Genomics, University of Montpellier, Montpellier, France
220 rdf:type schema:Organization
221 grid-institutes:grid.13097.3c schema:alternateName Department of Diabetes, School of Life Course Sciences, King’s College London, London, UK
222 schema:name Department of Diabetes, School of Life Course Sciences, King’s College London, London, UK
223 King’s College Hospital NHS Foundation Trust, London, UK
224 rdf:type schema:Organization
225 grid-institutes:grid.266100.3 schema:alternateName University of California, San Diego, CA, USA
226 schema:name University of California, San Diego, CA, USA
227 rdf:type schema:Organization
228 grid-institutes:grid.417226.4 schema:alternateName International Diabetes Center at Park Nicollet, Minneapolis, USA
229 schema:name International Diabetes Center at Park Nicollet, Minneapolis, USA
230 rdf:type schema:Organization
231 grid-institutes:grid.417924.d schema:alternateName Sanofi S.A., Paris, France
232 schema:name Sanofi S.A., Paris, France
233 rdf:type schema:Organization
234 grid-institutes:grid.8954.0 schema:alternateName UMC–University Children’s Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
235 schema:name UMC–University Children’s Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
236 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...